Sanofi-Aventis’ Semuloparin May Have Safety Advantage For ODAC To Consider
This article was originally published in The Pink Sheet Daily
Executive Summary
Unlike Pfizer and Eisai’s Fragmin (dalteparin), the new ultra-low-molecular-weight heparin does not appear to carry a hematoma risk.